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APOPTOTIC CELL DEATH PROMOTES AN IMMUNE EVASION 
PHENOTYPE IN TUMOR CELLS 
 
CONNOR B. DEVOE 
 
ABSTRACT 
 Cell death occurs by multiple pathways, though perhaps the most well-studied is 
apoptosis. Apoptosis describes a regulated, or programmed, form of cell death. While 
other forms of cell death, such as ischemic necrosis, occur via ATP-independent 
mechanisms, apoptosis is an ATP-dependent process that is reliant on intracellular 
enzymes known as “caspases”. Caspase-dependent cell death has been described as 
“death by a thousand cuts” as these proteases have a vast array of downstream targets 
which ultimately lead to chromatin condensation, extensive membrane blebbing and the 
formation of apoptotic bodies which are tagged for engulfment by professional and non-
professional phagocytes. 
While the machinery for cell death is expressed in all living cells, inhibitory 
proteins have been shown to exert control over apoptosis, particularly the B-cell 
lymphoma-2 (Bcl-2) protein and its family members. Bcl-2 itself is anti-apoptotic, 
alongside others such as Bcl-XL, Mcl-2 and Bcl-w. Others, such as BAK and BAX are 
pro-apoptotic and considered essential mediators of the mitochondrial outer membrane 
permeabilization characteristic of intrinsic apoptotic signaling. The highest level of 
control, however, appears to be exerted by the so-called “BH3-only” proteins, such as 
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BAD and BID, which disrupt Bcl-2-mediated antagonism of BAK/BAX and directly 
stimulate BAK/BAX activity. The balance of these proteins was described in the 
“Rheostat Model”, proposed in the 1990s by Stanley Korsmeyer and colleagues. The idea 
that oncogenic overexpression of anti-apoptotic proteins (i.e. the BCL-2 family) play an 
integral role in the survival and growth of tumors is a long-standing and well-supported 
hypothesis. 
Compared to necrotic cell death, apoptosis is considered relatively “silent” to the 
immune system, as it does not generate a large-scale inflammatory response. Engulfment 
of apoptotic cells by phagocytic cells is also known as “efferocytosis”, and results in the 
release of anti-inflammatory cytokines. One molecule integral in mediating efferocytosis 
is phosphatidylserine (PS), a signaling lipid externalized on the cell membrane in 
apoptotic cells. PS interacts with PS receptors to mediate resolution of inflammation 
through triggering the release of anti-inflammatory cytokines and directly preventing pro-
inflammatory cytokine release. Physiologically, this is a desirable process. Dysregulation 
of efferocytosis can lead to chronic inflammatory conditions, such as systemic lupus 
erythematosus. 
Recently, however, evidence has emerged supporting a role of apoptosis in 
signaling proliferation of neighboring cells in the tumor microenvironment. This stems 
from an understanding of apoptotic signaling in healthy tissues, such as wound 
regeneration, and the analogy of tumors as “wounds that do not heal”. Work by Andreas 
Bergmann and colleagues has demonstrated this apoptosis-induced proliferation (AiP) in 
Drosophila and described how this could translate to higher organisms including 
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mammals. Cells neighboring a site of injury where apoptosis is occurring in massive 
amounts may undergo compensatory proliferation. In the tumor microenvironment, 
where apoptosis is occurring, efferocytosis and AiP may work in concert to suppress an 
appropriate immune response and promote proliferation of neighboring cells. AiP may be 
further implicated in tumorigenesis and recurrence after treatment with apoptosis-
inducing chemotherapeutics. Sustained compensatory proliferation signaling may provide 
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Cell death is an inevitable and necessary component of the cell’s life cycle. An 
active area of research in many scientific disciplines, cell death has been shown to occur 
via a vast array of intra- and extracellular mechanisms. Depending on the type of death a 
cell is undergoing, cell-to-cell signaling and engulfment by phagocytic cells generates a 
plethora of consequences for cells immediately surrounding the dying cell, and perhaps 
even globally throughout the body. However, these consequences are not necessarily 
pathologic. Many common forms of cell death are highly regulated processes which work 
in concert with proliferation to homeostatically regulate the cellular environment. One 
such form of regulated cell death is apoptosis, which will be discussed at length in this 
thesis. Apoptosis differs from other forms of cell death in that it suppresses a larger 
immune response from happening; this is as if to say, “I am dying, but everything is OK. 
I am being cleared for the benefit of the cells around me.” 
Cancer is a disease with unquestionable global burden; in 2020, an estimated 16.9 
million Americans have a history of cancer, with a projected 1.8 million new cases set to 
emerge in the coming year1. With over 600,000 cancer-related deaths projected for 2020, 
cancer remains the 2nd leading cause of death worldwide. Additionally, medical costs of 
cancer and cancer-related complications in 2015 were $80.2 billion. Cancer as a disease 
is defined as an imbalance of cell proliferation relative to cell death. One theory suggests 
that dysregulation of regulated cell death (i.e. apoptosis) could lead to this unchecked 
proliferation and tumor formation, or “tumorigenesis”2. However, a deeper exploration of 
the mechanisms of cell death reveals a more sinister theory: apoptosis of tumor cells, 
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through suppression of an appropriate immune response, could be directly promoting 
neighboring tumor cell proliferation.  
This thesis aims to explore the underlying mechanisms of cellular death, 
particularly apoptosis, as they relate to neighboring cell proliferation and tumorigenesis. 
In doing so, this thesis will propose an explanation for the seemingly paradoxical 






The specific aims of this thesis are: 
  
 
1. Exploring current models, including cellular, animal and clinical, for evaluating 
apoptosis-driven immune evasion in tumors. 
 
2.  Investigating potential correlation of apoptotic index with clinical outcomes 





1.1 Characteristics of Apoptosis 
Various mechanisms of cell death have been described, and the origins of cellular 
death have important and widespread consequences. Programmed cell death is a term 
initially coined by Richard Lockshin in early work characterizing silkmoth development3. 
This study, as well as many others that followed, helped to explain predictable periods of 
cell death and their role in development. For example, one study indicates that 
triiodothyronine causes hormone-induced tail regression in tadpoles following 
upregulation of RNA and protein synthesis4. However, this tail regression can be 
suspended and led to survival of tails in vitro when RNA synthesis inhibitors were 
applied. Other examples of programmed cell death include apoptosis, a term initially 
coined in 1972 by Kerr, Wyllie and Currie, describes morphologically distinct form of 
programmed cell death which works synergistically with mitosis to homeostatically 
regulate cell proliferation5. Apoptotic cells undergo histologically organized processes 
prior to deletion. Pyknosis, or condensation and clumping of nuclear chromatin, and cell 
shrinking are two hallmarks of apoptotic cells6. Extensive blebbing and separation into 
fragments called “apoptotic bodies” enables phagocytosis via phagocytes; specifically 
“tingible body” macrophages, which contain nuclear debris from the engulfed apoptotic 
bodies7. These morphological changes observed in apoptotic body formation help 
illustrate the underlying molecular mechanisms of apoptosis (Figure 1).   
 
5 
Figure 1. Morphological Features of Apoptosis Left) Transmission electron micrograph 
depicting hallmark morphological signs of apoptotic cells including membrane blebbing 
and chromatin condensation; Right) Scanning electron micrograph showing a cell with 
hallmark signs of apoptosis. Images obtained from Purdue Cytometry CD-ROM Series, 
Vol. 4 8. 
 
1.2 Mechanisms of Apoptosis 
Since the initial characterization of apoptosis as a programmed form of cell death, 
three key pathways have been outlined. All three pathways appear to rely heavily on the 
family of aspartate-specific cysteine proteases, or caspases. The first caspase identified in 
the programmed cell death pathway was Ced-3, which was identified in the nematode C. 
elegans9. Through analysis of the genetic and protein structures of this molecule, Yuan et 
al. identified that it functioned similarly to the mammalian IL-1β converting enzyme 
(ICE) protein. The proposed role of this particular caspase (caspase 1, in humans) was in 
the proteolytic cleavage of inactive precursors to generate the mature form of the 
cytokine IL-1β10. Since then, other non-apoptotic roles for caspases have been proposed, 
such as immune system function, cell proliferation and cell structure remodeling11–13.  
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The first of three apoptotic pathways deemed the “extrinsic” or “death receptor” 
pathway, occurs through ligation of death receptors on the cell’s surface. These death 
receptors are members of the tumor necrosis factor (TNF) superfamily, and in addition to 
the primary ligand and its receptor, TNF-α/TNFR1, others such as the Fas ligand, 
FasL/FasR (CD95), can stimulate this pathway. Upon binding of the ligand, the proteins 
Fas associated via death receptor (FADD) forms a complex with caspase-8 (formerly 
known as FLICE). It should be noted that for the extrinsic pathway to occur, the death-
inducing signaling complex (DISC) must first be formed and always includes FADD and 
caspase-814. In this case, caspase-8 is acting as the “initiator” caspase, which cleaves the 
“effector” caspase-3 and -7. In fact, caspase-8 has been demonstrated as a “molecular 
switch” which regulates not only apoptosis via this pathway but is also involved in 
necroptosis and pyroptosis15. The “effector” or “executioner” caspase-3 and -7 have been 
shown to cause apoptosis by activation of the endonuclease CAD. In dividing cells, CAD 
is bound to its inhibitor ICAD, but the activated caspase-3 cleaves ICAD, freeing CAD to 
degrade chromosomal DNA (Figure 2) leading to the hallmark chromatin condensation 
observed by Kerr et al.5,16. It should be noted that there are a vast number of caspase 
substrates, leading to the phrase “death by a thousand cuts” often applied to caspase-
mediated cell death. While the exact number and mechanism of caspase-substrates 
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interactions is an active area of study, ICAD is integral to the chromatin condensation 
phenomenon. 
Figure 2. Extrinsic Apoptosis. 
The second pathway is known as the “intrinsic”, “classical” or “mitochondrial” 
pathway and serves as the major route to cellular apoptosis. This pathway is managed by 
a checkpoint of pro-apoptotic and anti-apoptotic signaling factors. The anti-apoptotic 
factors are members of the B-cell lymphoma 2 (Bcl-2) protein family, specifically Bcl-2, 
Bcl-xL, Bcl-w, Mcl-1 and A117. The pro-apoptotic factors, BAK and BAX are considered 
essential mediators of the intrinsic pathway and are regulated by the anti-apoptotic Bcl-2 
proteins. BID, described as a “BH3 domain only” due to its expression of only the BH3 
domain homology of the Bcl-2 protein, is involved in overwhelming the anti-apoptotic 
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signals to lead to cell death18 (Figure 3). Once activated, BID activates BAK and BAX to 
form oligomerized pores in mitochondria, inducing mitochondrial outer membrane 
permeabilization (MOMP). These pores in the mitochondrial membrane lead to the efflux 
of cytochrome c, which can complex with apoptotic protease-activating factor-1 (Apaf-
1), a protein with homology to Ced-4 in C. elegans, and caspase-9, forming an 
“apoptosome”19,20. In this intrinsic pathway, caspase-9 serves as the “initiator” caspase, 
and activation in an ATP-dependent manner triggers cleavage and activation of the 
effector caspase-3 and -7 (Figure 4) 
Figure 3. Comparative Gene Constructs of BCL-2 Family Members. Modified from 
Korsmeyer et al., 200018. 
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Figure 4. Intrinsic Apoptosis. Figure includes role of pro-apoptotic mitochondrial 
proteins SMAC (second mitochondrial-derived activator of caspase)21, HtrA2 (High-
temperature requirement serine protease A2)22, and ARTS (apoptosis-related protein in 
the TGF-beta signaling pathway)23 in promoting intrinsic apoptosis through inhibition of 
XIAP (X-linked inhibitor of apoptosis). 
 
The third apoptotic pathway is regulated by perforins, pore-forming proteins, and 
serine proteases, termed granzymes, which are both released by granules of cytotoxic T 
lymphocytes (CTLs) and natural killer (NK) cells. CTLs and NKs can also mediate the 
death receptor, extrinsic pathway of apoptosis, but they are crucial for mediating the aptly 
named “Perforin/Granzyme Pathway” of cell death. During immune surveillance, these 
immune cells utilize this pathway for unscheduled apoptosis of cells infected with viruses 
and other intracellular pathogens, as well as certain forms of cancer (i.e. B cell 
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lymphoma)24. Some granzymes cause cell death in a caspase-independent manner, which 
may include direct cytotoxic DNA damage25; others, such as Granzyme B, cleave BID 
(tBID) to trigger mitochondrial outer membrane permeability (MOMP) and cytochrome c 
efflux or cleave effector caspase-3 and -7 directly to trigger apoptosis26 (Figure 5).  





1.3 Homeostatic Regulation via Apoptosis 
Apoptosis is a necessary component of developmental processes and those which 
continue through adulthood. In mammals, apoptosis is critical during embryogenesis. The 
maintenance of homeostasis, a balance between cell survival and apoptotic death has 
been proposed through the so-called “rheostat” model (Figure 6). This model, proposed 
in the 1990s by Stanley Korsmeyer, suggested that the interaction of Bcl-2/BAX proteins 
could indicate a cell’s “resistance” (high Bcl-2/BAX ratio) or “susceptibility” (low Bcl-
2/BAX ratio) to apoptotic cell death27. The antagonism Bcl-2 demonstrates toward BAX 
was later shown to be disrupted by BH3-only homologs of the Bcl-2 family (i.e. BAD). 
BAD has been shown to free BAX from Bcl-2:BAX or Bcl-XL:BAX heterodimers, 
leading to restoration of apoptosis28. This model is supported by phenomenon seen in 
vivo, as in lymphoma where a Bcl-2:BAX ratio prevents apoptosis and sustained cell 
growth of these tumor cells, perhaps even in the presence of chemotherapeutic-induced 











Figure 6. Rheostat Model of Apoptotic Control. Depicted as a lightbulb dimmer (an 
example of a rheostat), this model demonstrates how the presence of Bcl-2, BAX/BAK 
and BH3-only proteins determines the relative levels of apoptosis. Without BAX/BAK, 
Bcl-2 drives an anti-apoptotic phenotype and cells persist (unless there is a second 
mutation). Bcl-2-mediated antagonism in the presence of BAX/BAK helps preserve 
homeostatic levels of proliferation and death. In the presence of the BH3-only proteins, 
Bcl-2 is inhibited and BAX/BAK activated to drive a pro-apoptosis phenotype. 
 
This interplay between the pro-apoptotic and anti-apoptotic members of the Bcl-2 
family has since been expanded upon, and mRNA expression levels vary at critical time 
points of embryonic development. In the earliest stages of embryonic development, 
mRNA for BCL2L10 (also known as BCL-B or DIVA) is highest, although these levels 
wane with continued division30. BCL2L10 is thought to prevent apoptosis during these 
early stages, and this anti-apoptotic mRNA is inherited maternally. By day 3 however, 
when the number of cells reaches 6-8, the embryonic genome is activated, and high levels 
of the pro-apoptotic mRNA are observed. It is hypothesized that this provides an 
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increased sensitivity to apoptosis at this stage, given that these embryos produce higher 
levels of pro-apoptotic mRNA than mature MII oocytes and day 5/6 blastocysts30. 
The anti-apoptotic gene Mcl-2 is essential in embryonic development, as 
demonstrated by Mcl-2-/- mice. In these mice, blastocysts fail to implant, resulting in 
embryonic lethality. However, these cells do not show elevated levels of apoptotic 
activity, and the inner cells mass is capable of growing in vitro, suggesting the 
importance of Mcl-2 in preimplantation development and adhesion31. Additionally, as 
levels of Mcl-2 mRNA rise, Bcl-XL mRNA become elevated. Evidence from knockout 
studies suggests that these two genes work in concert with each other, with distinctive 
individual functions, particularly in neurogenesis. The two are temporally distinct, with 
Mcl-2 importance in neuroprecursor cells (NPCs) and a prominent role for Bcl-XL in 
mature neurons, with both acting on BAX. Of note, in Mcl-2 knockout mice, Bcl-XL can 
partially compensate for a loss of Mcl-232. Additionally, individual knockout studies 
indicate that lack of anti-apoptotic effects of these genes do not lead to immediate cell 
death, but rather autophagic death of neurons with a lack of Mcl-2, or increased 
sensitivity to apoptosis in cells deficient in Bcl-XL33,34. Knockout of both genes, however, 
leads to a complete loss of the nervous system32. Bcl-XL also demonstrates protection 
from apoptosis in newly differentiated neurons in mice35. 
The Bcl-2 protein and family members are conserved across species and 
homologous proteins carry out similar functions in processes such as apoptosis (Figure 
7). While the function of anti-apoptotic genes such as BCL2L10, Mcl-2, and Bcl-XL 
demonstrate clear importance in embryonic and nervous system development, pro-
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apoptotic proteins are equally as crucial. In these processes, cells are over-produced, and 
pruning and plasticity are necessary and regulated by programmed cell death. 
Particularly, in nervous system development, both the extrinsic and intrinsic pathway 
have been demonstrated in both NPCs and post-mitotic neurons. Mice deficient in the 
pro-apoptotic protein Apaf-1 demonstrate extensive cell growth in the periventricular 
proliferative zone and die during embryonic death36. This activation of the intrinsic 
pathway appears to be due to a lack of trophic factors in both NPCs and post-mitotic 
neurons37. 
Many other homeostatic roles for apoptosis have been demonstrated. Wound 
healing, for example, involves the migration of many cells to the site of injury. Thus, the 
body requires a mechanism by which to clear these cells to ensure proper healing, and 
apoptosis provides a mechanism that does not potentiate further inflammation. 
Additionally, key signaling pathways occur upon apoptosis of neutrophils, which have 
migrated to the site of injury and released their contents. Apoptotic neutrophils are taken 
up by macrophages via efferocytosis and the macrophages shift from a pro-inflammatory 
to anti-inflammatory phenotype38. Without this key transition, wounds become non-
healing.  
B and T lymphocyte maturation provides another instance of physiologic 
apoptosis. Programmed death of defective cells in the marrow or thymus is crucial to 
successful maturation B and T cells. Additionally, upregulation of anti-apoptotic Bcl-2 
family member mRNA promotes cell survival of both pro-T and pro-B cells. Specifically, 
upregulation of Mcl-2 mRNA promotes survival of these cells during development, and 
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at ablation of the gene results in rapid cell death39,40. The best example of this is seen in 
the upregulation of BAX and PUMA (both BH3-only proteins) by p53, a major cell cycle 
regulatory protein, following DNA damage41. Likewise, loss of Bcl-XL results in rapid 
death of immature (CD4+/CD8+) thymocytes and prevents appropriate maturation42. 
Figure 7. Cross-Species Conservation of Apoptotic Elements. Modified from Fuchs 
and Stellar, 201143. 
1.4 Pathological Implications of Apoptosis 
Abnormal apoptosis can lead to pathological presentation; too much apoptosis can lead to 
degenerative disease, while too little apoptosis can lead to unchecked proliferation and 
can lead to carcinogenesis.  
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2. Other Forms of Cell Death 
2.1 Necrosis 
In contrast to the programmed cell death in apoptosis, necrotic cell death is characterized 
by the uncontrolled release of cellular components following loss of integrity and 
eventual lysis of the cell membrane. Necrotic cell death is typically brought on by toxins, 
hypoxia, or traumatic damage to the cell, triggering membrane permeabilization, cellular 
swelling and rupture44 (Figure 8). The process of cellular swelling, as opposed to the 
cellular shrinkage observed in apoptosis, is known as oncosis. This process is 
characterized by swelling, karyolysis, or dissolution of the nucleus, and vacuolation prior 
to cell lysis45. Considering necrosis as an antonym of apoptosis is convenient for the sake 
of comparison, although the two are not mutually exclusive. As apoptosis is an energy-
dependent process, if a cell exhausts its stores of ATP, the cell may switch from 
apoptosis to necrosis. This is called secondary necrosis, characterized by swelling and 
lysis of previously apoptotic cells. Also, if oncosis is inhibited, cellular stresses may 















Figure 8. Morphological Features of Necrosis. Comparison of morphological features 
of a) normal cell; b) autophagic cell (survival); c) apoptotic cell (dying); and d) necrotic 
cell. Note d) demonstrates the characteristics of necrotic cell death including selling, 
karyolysis and vacuolation prior to cell lysis. Scale represents 1µm. Image taken from 
Edinger & Thompson, 200446.  
 
Programmed necrosis is also characterized by mitochondrial swelling and rupture, 
a process preceded by the phenomenon, “Mitochondrial Permeability Transition” 
(MPT)47,48. This process is triggered by pathological levels of calcium and ROS, although 
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the exact mechanisms underlying MPT are still under active investigation. Important in 
the formation of the pore leading to increased inner mitochondrial membrane 
permeability is the mitochondrial protein cyclophilin D (aka, peptidylprolyl isomerase F, 
PPIF). Loss of this protein in PPIF-/- mice shows protection from ischemia/reperfusion-
induced cell death49. This phenomenon has been important to observe in medicine 
because blocking cyclophilin D activity via pharmacological application of cyclosporine 
A appears to be cardioprotective following ischemic injury50. This phenomenon has been 
duplicated experimentally, limiting reactive oxygen species (ROS) production, 
inflammation and mitochondrial decoupling following aortic cross-clamping related 
ischemic injury in rats51. Studies to show cardioprotective effects of cyclosporine A have 
shown mixed results, but it remains an optimistic therapeutic modulator of ischemic 
injury. Whereas MPT occurs on the inner mitochondrial membrane, Bcl-2 family 
members BAX/BAK have been shown to function as the outer mitochondrial pore 
contributing to MOMP (Figure 4), and could provide another possible therapeutic 
target52.  
Necrosis occurs in two primary forms: Liquefactive and coagulative. These are 
based micro- and macroscopic changes to cells. Death by complete or partial dissolution 
of dead tissue into a liquid mass as a result of bacterial or fungal infections, or other 
inflammatory stressors indicates liquefactive (or colliquative) necrosis. In coagulative 
necrosis, cells maintain most of their normal architecture several days after death, but 
cellular swelling and microscopic changes indicate coagulative necrotic death53. For 
example, a lack of nuclei and hypertrophic appearance in cardiac myocytes following 
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acute infarct53,54. As highlighted by Adigun, Basit and Murrary53, distinctive clinical 
presentations have generated subsets of necrotic death. Caseous cell death, observed with 
bacterial tuberculosis infection, forms granulomas: eosinophilic centers surrounded by 
lymphocytes and activated macrophages leading to the cheese-like (caseous) 
appearance53,55. Fat necrosis, where adipocytes lyse to release digestive enzymes which 
break down lipids forming free fatty acids leading to anucleated adipocytes and calcium 
deposits53,56. Although not macroscopically difficult to distinguish, fribrinoid necrosis is 
another clinical subset used to describe the deposition of fibrin associated with vascular 
damage, as seen with immune-complex disease following a type III hypersensitivity 
reaction53,57,58. Similarly, gangrenous necrosis is clinically used to distinguish black skin 
with putrefaction in the limbs and is microscopically a combination of coagulative, due to 
ischemia, and liquefactive, with underlying bacterial infection, necrosis53. 
 
2.2 Necroptosis 
As previously mentioned, apoptosis and necrosis are not entirely distinct, and 
there is speculation that they even exist as two ends of a spectrum of cell death. A 
regulated form of necrotic cell death, known as necroptosis, is one example of how these 
two processes are related. Like apoptosis, necroptosis relies on signaling from cell 
surface receptors, specifically death receptors such as tumor necrosis factor receptor 1 
(TNFR1). This receptor is reliant on a necrosome, where receptor-interacting proteins 1 
(RIP1) and 3 (RIP3) form an amyloid-like hetero-oligomeric signaling complex of 
protein aggregates59. Upon binding of the ligand, TNFR1 recruits a pro-survival complex 
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1 containing TNFR-associated death domain (TRADD), RIP1 and ubiquin E2 ligases 
which polyubiquitinate RIP1. Following deubiquitination of RIP1 a decision is made; 
either RIP1 is deubiquitinated and complex IIa is formed, triggering caspase 8 and 
subsequent extrinsically-mediated apoptosis, or complex IIb is formed, caspase 8 is 
inhibited, and necroptosis is activated60. Recruitment and phosphorylation by RIP3 
triggers formation of another signaling complex, the mixed lineage kinase domain-like 
(MLKL) pseudokinase, which, following oligomerization, induces loss of membrane 
integrity and necrotic death61. This signaling complex is known as the “necrosome”, and 
it is believed to poke holes in the cell membrane to cause necroptosis.  
Despite its regulated, procedural activation, necroptosis is contrary to apoptosis in 
that it is a pro-inflammatory mechanism of cell death. This mechanism is believed to be 
due to, at least in part, nuclear factor-kappa B (NF-κB). In response to viral infection, 
endosomal toll-like receptors (TLR) 3, 7 and 8 are activated, and downstream signaling 
activates interferon regulatory factor (IRF) transcription, producing multiple components 
including interferon beta (IFN-β) and NF-κB62. The specific molecule responsible for 
activating transcription is the IFN-inducible protein DNA-dependent activator of IRFs 
(DAI)63. Shortly after discovery of this molecule, Rebsamen and colleagues observed that 
DAI recruits RIP1 and RIP3 through specific RIP homotypic interaction motifs (RHIMs) 
and activates NF-κB signaling, potentiating the pro-inflammatory consequences of 




A third type of programmed cell death is characterized by the release of a “net”-
like structure of chromatin- and histone-containing fibers known as neutrophil 
extracellular traps (NETs)65. Originally characterized in neutrophils, NET-like structures 
can also be extruded by other hematopoietically-derived cells including mast cells66, 
eosinophils67, and basophils68. Primarily a response to microbial pathogens, NETosis can 
be triggered by microbial signals including lipopolysaccharide (LPS) via TLRs69,70. 
Although the intracellular mechanisms which trigger NET extrusion are the subject of 
some debate, there is agreement that this mechanism is dependent on intracellular ROS. 
This has been demonstrated pharmacologically by the rescue of neutrophilic NET 
extrusion following both exogenous H2O2 administration and via gene therapy in patients 
with chronic granulomatous disease (CGD) who otherwise cannot generate ROS or 
NETs71,72. The mechanism by which NETotic cell death occurs is also under debate. As 
highlighted by the 2018 Nomenclature Committee on Cell Death, it is thought that the 
Raf-MAPK-ERK2 pathway activates ROS generation, driving release of neutrophil-
expressed elastase, ELANE, and myeloperoxidase (MPO). This simultaneous release 
promotes the MPO-dependent proteolytic activity of ELANE and drives cytoskeleton 
damage and chromatin decondensation, leading to plasma membrane rupture73. 
Interestingly, NET extrusion does not necessarily result in cellular lysis, and NETs have 




First proposed in 2012 by Dixon et al.76, ferroptosis represents a morphologically 
and microscopically distinct type of random cell death. This mechanism is apparently 
dependent upon the toxic accumulation of ROS. Morphologically, ferroptosis is 
characterized by small mitochondria, with condensed mitochondrial densities and either 
reduced or lost mitochondria cristae, as well as outer mitochondrial membrane rupture. It 
is suspected that these changes are due to high levels of lipid peroxidation and oxidative 
stress77. High lipid peroxidation can trigger aberrant iron metabolism, leading to 
reduction by the metalloreducatase STEAP3 from Fe3+ to Fe2+, enabling transport by the 
divalent metal transporter 1 (DMT1). High intracellular iron levels leads to ROS 
production and accumulation by the Fenton reaction78. It would appear that this system is 
endogenously regulated by the reduced glutathione (GSH) dependent peroxidase GPX4, 
as knockdown and overexpression studies of GPX4 have been linked to direct control of 
ferroptotic acitivity79. More recently, the role of GPX4 in inhibiting ferroptosis has been 
linked to the prevention of phosphatidylethanolamine-containing polyunsaturated fatty 
acids (PUFAs), such as arachidonic and adrenic acids, which would otherwise act as 
death signals80. 
2.5 Autophagy 
Autophagy is the major homeostatic process by which cytosolic components of 
cells are degraded and recycled via the lysosome81. The initial step of autophagy is the 
formation of the phagophore via formation of the ULK1 (unc-51-like kinase 1) complex, 
and the class III phosphoinositide 3-kinase (PI3K) complex81. This complex contains 
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many components including VPS (vacuolar protein sorting) proteins VPS34 and VPS15, 
autophagy-related protein (ATG) 14L (ATG14-like), and BECLIN-1. Upon formation of 
these complexes, the phagophore elongates, utilizing the ATG5-ATG12-ATG16 complex 
and lipidated microtubule-associated protein light chain 3 (LC3II). The developed 
autophagosome, which contains the organelles and cytosolic proteins targeted for 
degradation, then fuses with the lysosome and undergoes degradation via lysosomal 
hydrolases82. 
Of note, three major forms of autophagy have been identified, as summarized by 
Cuervo, 2004; macroautophagy, microautophagy and selective autophagy83. In 
macroautophagy, entire cellular cytosolic compartments are separated in double-
membrane vesicles which fuse with lysosomes for degradation. Microautophagy is 
slightly more specific, as the organelles fuse directly with lysosomes, which occurs via 
the tagging of these organelles with surface proteins to trigger lysosomal fusion84. 
Finally, in selective autophagy (a.k.a. chaperone-mediated autophagy), heat shock protein 
HSC70 works with cochaperones such as HSP40 (a.k.a. DNABJ1) and HSP70-HSP90 
organizing protein (HOP) to guide proteins to the lysosome-associated membrane protein 
type 2A (LAMP2A) for their selective degradation85. Autophagic mechanisms for 
promoting cell survival, such as aiding in the removal of toxic protein aggregates, are 
more deeply understood than roles in cell death. In recent years, efforts been made to 
clarify if autophagy directly causes cell death or simply accompanies and aids existing 
mechanisms of cell death86. It is most likely that autophagy is a survival mechanism, 
whereby cells delete cellular components to maintain a basal metabolic rate. These cells 
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will only die after periods of prolonged starvation, or if they have a viral infection. In the 
latter case, it is most likely immune-mediated where NK cells or CTLs would induce 
granzyme/perforin-mediated apoptosis of the infected cell.  
2.4 Pyroptosis 
Pyroptosis is a programmed form of necrosis. Initially, pyroptosis was described as 
caspase-1 mediated cell death, due to the caspase-1-dependent formation of ion pores in 
the plasma membrane which is leads to pathological efflux of ions and cellular lysis87. 
Caspase-1, as initially mentioned, is also known as ICE – interleukin (IL) converting 
enzyme and is responsible for production of IL-1β10. It has since been discovered that the 
mechanism of activation for pyroptosis is two-fold: First, a signaling cascade from 
pattern recognition receptors (PRRs) pathogen-associated microbial patterns (PAMPs) 
triggers formation of the inflammasome. This activates the cleavage of caspase-1 from 
the zymogen procaspase-1. Activated caspase-1 can then trigger the activation of IL-1β 
from pro-IL-1β, leading to activation of gasdermin D (GSDMD), a substrate 
representative of a large family of pore-forming proteins. The second pathway is 
triggered specifically by LPS, which causes activation of caspase-4/5/11 (via cleavage 
from procaspase-4/5/11), which activate GSDMD and pore formation88. 
 
3. Physiological and Pathological Fates of Apoptosis 
3.1 Efferocytosis 
As important as the balance between mitosis and apoptosis is in maintaining 
homeostasis is the clearance of apoptotic bodies by surrounding cells, a process known as 
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efferocytosis. This term, coined by Henson et al.89, comes from the Greek “to bury”, and 
has been researched in greater depth in recent years. Professional phagocytic cells, such 
as macrophages (Figure 9) and dendritic cells, are believed to be the primary mediators 
of efferocytosis. However, neighboring non-professional or “amateur” phagocytic cells, 
such as epithelial/endothelial cells, fibroblasts and microglial cells have demonstrated 
capacity for efferocytosis, though with varying levels of efficiency90,91. 
 
Figure 9. Efferocytosis of Apoptotic Bodies via Efferocytes. A) Uptake of intact 
apoptotic bodies by macrophages, dendritic cells or other efferocytes. Apoptotic bodies 
displaying cell-surface signals are engulfed via membrane extensions. B) Recent 
evidence suggests that these signaling molecules act as barcodes, and that efferocytes can 
modify the cytokines released following efferocytosis to potentiate cell-death outcomes.  
Image obtained from Kumar & Birge, 201692. 
 
Various genes have been implicated in efferocytosis, starting in the model organism C. 
elegans. In 2001, Zhou et al. demonstrated the role of the ced-1 gene and protein product 
as a transmembrane scavenger receptor which mediates engulfment with neighboring 
cells93. Since then, a pathway has been elucidated between ced-1, ced-7, an analogue of 
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the ABC-1 cassette transporter94, and ced-6, which contains a phosphotyrosine domain 
and is integral in mediating engulfment signaling95,96. This pathway works in conjunction 
with a pathway involving ced-2, ced-5, ced-12 and ced-10, a conserved pathway in 
Drosophila and mammals which triggers signaling of engulfment of the dying cells97. 
Additionally, ced-8 encodes a lipid scramblase, which is important in the externalization 
of phosphatidylserine (PS), an integral “eat-me” signaling lipid98.  
These intracellular signaling pathways are highly conserved across species, 
including Drosophila and mammals, with each ced gene possessing a counterpart 
homolog/analogue (Table 1). Ced-1 corresponds to the CD91/scavenger receptor from 
endothelial cells (SREC)-like protein, while ced-7 corresponds with the ABC1 
transporter (Eato in Drosophila), and ced-6 with the GULP adaptor protein, which binds 
the CED-1 or CD91/LRP (low density lipoprotein receptor-related protein) 
phosphotyrosine domain99–101. CED-8 has been shown to function similarly to the Xk-
related protein 8 (Xkr8), a mammalian scramblase promoting externalization of PS98. 
Additionally, the ced-2, ced-5, ced-12 pathway appears to function identically to the 
CrkII, DOCK180 (mammals), ELMO1 pathway in mammals. Ced-5 is analogous to the 
Drosophila homolog myoblast city (Mbc), and its function in apoptotic clearance in 
Drosophila development is essential102. Ced-10 demonstrates GTPase activity equivalent 
to Rac1 in mammals97,103.  
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Table 1. Conservation of Engulfment Signaling Molecules from C. elegans, 
Drosophila and Mammals. 
3.2 Resolution of Inflammation 
As previously mentioned, the externalization of PS is a key step in efferocytosis 
which ultimately dictates engulfment of the dying cell. While the C. elegans model has 
provided an excellent framework of the proteins involved in triggering efferocytosis, 
PS/PS receptor (PSR) signaling is a complexed and nuanced phenomenon which is best 
studied in higher metazoans. A myriad of PSRs have been identified, as well as their 
complementary ligands. These receptors include stabilin-1 and stabilin-2, the TAM 
(Tyro, Axl, Mer) family of receptors, the integrins αvβ3/5, the T cell immunoglobulin 
mucin 1 (TIM-1, as well as TIM-3 and TIM-4), the CD300 family (CD300b and 
CD300a), as well as BAI1104. These receptors interact with PS differently: BAI1 is a 
transmembrane protein which interfaces directly with PS, triggering signaling via ELMO 
and DOCK180, whereas Mer or αvβ3/5 integrins are tyrosine kinases which require 
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ligands (GAS6 or protein S for TAMs, milk fat globule-EGF factor 8 protein (MFG-E8) 
for integrins) to interface with PS and trigger signaling105,106. The increasing numbers of 
PS-PSR interactions identified in recent years make clear the underlying complexity of 
PS signaling in the clearance of apoptotic cells. As Kumar et al.107 point out in their 
review of efferocytosis, multiple PS receptors are often activated simultaneously leading 
to cooperative and synergistic downstream signaling. Thus, it is sensible to consider a 
“phagocytic synapse”, analogous to the immunological synapse in T cell signaling, when 
discussing PS signaling.  
3.3 Consequences for Immune Response (Signaling Factors) 
Being the prominent “eat me” signal, PS-PSR signaling has an important role to 
play in programmed cell death, specifically, in preventing potentially harmful immune 
responses.  Improper clearance of apoptotic cells can be both the cause and effect of 
chronic inflammatory diseases. As discussed, if cells fail to complete apoptosis (i.e. due 
to ATP depletion), cells can enter secondary necrosis and lyse. Secondary necrosis has 
been implicated in autoimmune diseases, such as systemic lupus erythematosus (SLE). 
Interestingly, apoptotic remnants in the germinal follicular centers, possibly presented via 
tingible body macrophages, can result in autoimmune antibody production, triggering 
SLE108. Additionally, damage to skin cells by UV light can trigger accumulation of 
autoantigens, and cause flares in SLE patients and potentially immune complex 
formation, undoubtedly contributing to chronic inflammation in these patients109,110. 
Autoantibody production has also been linked directly to impaired efferocytosis111,112.  
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Ensuring proper management of “eat me” signals is therefore necessary to maintain 
homeostasis and prevent the etiology and pathogenesis of chronic disease. Two 
prominent classes of PSRs have been shown to directly inhibit the production of pro-
inflammatory cytokines. The TAM receptor Axl, in conjugation with its ligands GAS6 
and Protein S, suppresses TLR signaling and prevents expression of pro-inflammatory 
cytokines TNF-α, IL-1β and IFNα113,114. Similarly, Mertk receptor signaling results in a 
blockade of NF-κB and pro-inflammatory cytokine release by dendritic cells115. The TIM 
family of PSRs possess immunoreceptor tyrosine-based inhibitory motifs (ITIMs), and, in 
addition to serving as tethering receptors in the “phagocytic synapse” and activating T 
cell responses, have been implicated in suppressing pro-inflammatory signals116,117. 
Genetic ablation studies have implicated the role of these suppressive signals in 
preventing autoimmune and chronic inflammatory conditions. Selective ablation of Axl 
or GAS6 leads to impaired recovery of neurons after pharmacologically-induced 
damage118–120. However, exogenous GAS6 was sufficient to provide therapeutic rescue 
following pharmacologically-induced damage121. Additionally, a genome-wide analysis 
of over 9,000 patients has implicated a link between polymorphisms of Mertk and 
development of multiple sclerosis122. Conversely, increasing efferocytotic clearance of 
apoptotic cells, such as through increased BAI1 expression, has been shown to reduce 
inflammation in chronic inflammatory disease123. 
Equally as important in suppressing harmful inflammatory responses following 
apoptosis is the release of so-called “calming” agents, such as TGF-β, IL-10, adenosine 
diphosphate (ADP), prostaglandin E2 (PGE2) and thrombospondin-1 (TSP-1). This 
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process of tempering the inflammatory response following apoptotic activity is termed 
“catabasis”124. In addition to these signaling factors, a host of endogenous mediators 
work in concert to mediate this resolution of inflammation, known as resolvins, protectins 
and lipoxins125. These molecules appear to operate on a switch, with chemical signals 
influencing which lipid mediators are produced. For example, PGE2 specifically switches 
production of damaging, pro-inflammatory leukotrienes and prostaglandins to anti-
inflammatory lipoxins, such as lipoxin A4
126. Additionally, PGE2 appears to upregulate 
production of pro-resolution factors such as E-series and D-series resolvins and 
protectins125. Other factors, such as the local secretion of vascular endothelial growth 
factor (VEGF) by Mertk and Mfge8 expressing macrophages, have shown to be critical in 
repairing injury following myocardial infarction127. Faulty resolution of inflammation is 
hypothesized to result in chronic inflammatory conditions, such as chronic obstructive 
pulmonary disease (COPD)128. 
One major complementary pathway which assists in appropriate efferocytosis and 
catabasis is alternative macrophage activation to a so-called, anti-inflammatory “M2” 
phenotype. This appears to mediated, at least in part, by the secretion of TGF-β129. 
Physiologically, a balance of M1 (classically activated) and M2 macrophages exists. A 
shift in this balance is seen during human development and pregnancy (M2 polarization), 
and during pathogenesis (M1 polarization) such as in atherosclerosis or obesity130. A 
polarization toward M2 phenotype is favorable following apoptosis, as seen following 
ischemic/reperfusion liver injury after surgery which is mediated by D1 resolvins131. In 
2014, Das et al. demonstrated the importance of microRNA-21 (miR-21) in polarizing 
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macrophages toward an anti-inflammatory M2 phenotype in wound healing132. In a recent 
study, the same group demonstrated that a modified collagen gel dressing improved 
wound healing through increased production of anti-inflammatory IL-10, IL-4 and pro-
angiogenic VEGF due to increased macrophage recruitment and upregulation of miR-
21133. In summary, efferocytosis of PS-expressing cells drives macrophages to express an 
M2, anti-inflammatory phenotype. 
4. Consequences of Pathological and Chronic Apoptosis 
4.1 Compensatory Apoptosis-Induced Proliferation 
Externalization of PS and PS/PSR signaling are just one downstream consequence 
of caspase activation via apoptosis. Compensatory proliferation, a mechanism of 
replenishing lost tissue due to damage or injury, is another such consequence. Although 
regenerative capacity varies greatly across species, it is apparent that compensatory 
proliferation is necessary to repair tissue following injury, and following apoptosis. Early 
work in Drosophila characterized a unique form of compensatory proliferation, reliant on 
apoptotic machinery and specifically the initiator caspase Dronc. Since then, the term 
“apoptotic-induced proliferation” (AiP) has been used to describe compensatory 
proliferation coupled with apoptotic activity134.    
Andreas Bergmann and colleagues at the University of Massachusetts Medical 
School have proposed a three-part model for AiP in Drosophila melanogaster: “Undead”, 
“genuine” and “post-mitotic”135 (Figure 10). The first model (Figure 10A), also known 
as the “overgrowth” model, occurs when apoptotic cells exist in an immortalized state, 
primarily due to the expression of the caspase inhibitor p35. In this “undead” cell, the 
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transporter Myo1D carries Dronc (the initiator caspase in Drosophila) to the membrane, 
inducing the NADPH oxidase Duox to generate ROS136. Macrophages attracted to the 
“undead” cell release the TNF ligand Eiger, which activates the JNK stress-signaling 
pathway; this in-turn leads to expression of hid and reaper, creating an amplification 
loop137,138. Additionally, JNK signaling causes the release of proliferation factors, such as 
Dpp, Wg, and Spi 139,140. The combination of the amplification loop perpetuating Dronc 
signaling and the release of these proliferative factors provides a convincing model for 
unchecked proliferation in the “undead” model of AiP.  
The second model, also known as the “regenerative” model (Figure 10B), occurs 
independent of p35 and is more conservative. Spatial and temporal restrictions are placed 
on dying cells in order to prevent excessive apoptosis. This model relies on JAK/STAT 
and p53 signaling in addition to the JNK signaling observed in the “undead” model of 
AiP. ROS generation appears to occur intracellularly, propagating the signal to 
neighboring cells where the JNK pathway is activated; p38 signaling through Akt and the 
redox-sensitive Ask1 factor induce expression of Unpaired (Upd), which is an IL-6 
paralog141. Unlike the “undead” model, the role of proliferative signaling factors is 
undefined in the “genuine” model, and this may provide an explanation for the context-
dependent nature of AiP. The third model, “post-mitotic” AiP (Figure 10C), is best 
demonstrated in the developing retina of Drosophila, as dying photoreceptor neurons 
produce and secrete the mitogen Hedgehog (Hh) in a DrICE/Dcp1-dependent manner142, 
promoting proliferation of neighboring, undifferentiated (yet post-mitotic) cells. Contrary 
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to the “undead” and “genuine” models of AiP, this model relies on the Hippo signaling 
pathway, rather than JNK143.  
34 
35 
Figure 10. Apoptotic-induced Proliferation (3-Part model). Proposed 3-part model of 
apoptotic-induced cellular proliferation in Drosophila. A: The “undead” model is in an 
immortalized cell, which possess the caspase inhibitor p35. Production of ROS recruits 
macrophages to secrete cytokines (i.e. TNF) which activate the JNK pathway and induces 
an amplification loop which initiates unchecked proliferation. B: The “genuine” or 
“regenerative” model, in which intracellular ROS production promotes cell proliferation 
but temporal and spatial restrictions provide a check on this proliferation. C: The 
“proliferative” or “post-mitotic” model in which proliferation is triggered by the secreted 
Headgehog mitogen (Hh) and the pathway does not involve JNK signaling. This pathway 
is observed in the developing retina in Drosophila. Figure taken from Diwanji and 
Bergmann135. 
4.2 Apoptotic Index (including prognostic research) 
The fundamental principles of chemotherapy are to kill rapidly dividing cells  
as a means of “targeting” tumor cells. Given the lack of a concurrent inflammatory 
response, death by apoptosis would be the preferred mechanism for chemotherapeutic 
agents. With that in mind, why would a high number of apoptotic cells in the tumor 
microenvironment not be indicative of a good prognosis for cancer patients? This can be 
quantified, via the number of apoptotic cells per 100 intact neoplastic nuclei113, otherwise 
known as the “apoptotic index” (AI). Existing theories, and a simplistic perspective, 
would lend credence to the idea that high levels of apoptosis (high AI) could overwhelm 
the rapid division and prevent tumor proliferation. However, as this thesis has discussed, 
apoptosis is a complex phenomenon influencing many other factors and involving 
prolific cell-to-cell communication. It is possible that, in certain cancers, a high AI could 
create an overall immunosuppressive tumor micro-environment, promoting immune 
escape, tumorigenesis and unchecked proliferation.  
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Examining Bergmann’s model of AiP in Drosophila, the “undead” model could 
provide a model for the tumor microenvironment. In this model, the abundance of p35, 
the caspase inhibitor, results in the complexing of DRONC with Myo1D and DUOX to 
produce ROS and locally recruit macrophages135. High pro-inflammatory cytokines are 
thus produced by the recruited macrophages, such as TNF-α. The presence of ROS, 
activated macrophages and continued cytokine release leads to activation of JNK 
signaling pathways, promoting an amplification loop and unchecked proliferation with 
apoptosis prevented by p35. Cyclin dependent kinase 5 (Cdk5), a downstream target of 
p35, has been shown to be dysregulated in cancer and associated with poor prognosis. 
Thought to be upregulated in response to DNA damage, Cdk5 triggers STAT3 signaling 
pathways and upregulates pro-survival factors. Inhibiting Cdk5 is associated with 
decreased tumorigenesis, proliferation and metastasis further underscoring its 
importance145. The role of Cdk5/p35 signaling in human carcinomas could provide 
evidence of the “undead” model of AiP as a mechanism of high AI resulting in 
tumorigenesis and potentiating poor prognosis. 
In 1999, Tanaka et al.146 described a study of 236 patients undergoing surgery for 
previously untreated non-small cell lung cancer (NSCLC) and analyzed both AI and 
proliferative index (PI). After stratifying the patients across lowest AI (AI <5.0), lower 
AI (5.0 ≤ AI < 11.0), higher AI (11.0 ≤ AI < 25.0) and highest AI (25.0 ≤ AI), the group 
determined 5-year survival rate. The group found that the lower, higher and highest AI 
groups also had higher PI (48.0%, 54.3% and 50.7%, respectively), and the lower and 
higher groups had poorer prognosis than the lowest AI group (PI=32.3%). They 
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concluded that AI is suitable as an independent prognostic factor in NSCLC. The study 
used the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) 
labelling technique147. PI is measured by the presence of the antigen Ki-67, a marker of 
proliferation. 
Studies emerging after Tanaka et al. shared mixed results, but several studies have 
supported the idea that AI could provide prognostic value. One group correlated AI with 
proliferating cell nuclear antigen (PCNA) and several other biomarkers in NSCLC 
patients, and found that individuals with high PCNA and high AI have a particularly poor 
prognosis148. Several other studies have corroborated this idea in other cancers, including 
non-Hodgkins lymphoma144, endometrial adenocarcinoma149, synovial sarcoma150, 
prostate carcinoma151, squamous cell lesions of the oral cavity152, breast cancer153 and 
bladder cancer154.  
4.3 Immune Evasion  
Long understood is the concept of tumors as “wounds that do not heal”155. As such, the 
tumor micro-environment is a rich inflammatory environment with competing signaling 
molecules dictating tumorigenesis. In support of this analogy, the tumor micro-
environment is rich in macrophages, termed cancer associated macrophages (CAMs), 
which express M2-like phenotype. This appears to be due to high levels of IL-10, IL-4, 
IL-13 and glucocorticoids156,157. This might be due to high levels of efferocytosis of 
apoptotic cells, and thus indicates a hijacking of a physiologically beneficial pathway. In 
addition, the tumor micro-environment contains high levels of macrophage colony-
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stimulating factor (M-CSF) and TGFβ, which potentially play a role in polarizing 
developing monocytes into M2-like macrophages158.  
The M2-like phenotype would theoretically be ideal in this environment; 
however, the immunosuppressive secretions of CAMs are likely diminishing an 
appropriate immune response to the tumor. In fact, one study has demonstrated that 
intracellular adhesion molecule-1 (ICAM-1) is involved in mediating macrophage 
polarization. ICAM-1 deficient mice demonstrate increased M2 macrophage infiltration 
and accelerated liver metastasis of colon carcinoma; however, when efferocytosis is 
inhibited, these cells show diminished metastatic capacity and lacked M2 macrophage 
polarization159.  
TNF and IL-6 are also elevated in the tumor micro-environment and lead to NF-
κB activation via the classical, inhibitor-of-NF-κB kinase-β (IKKβ) pathway. This 
activation has been implicated as an essential promoter of inflammation-associated 
carcinomas160. Not only does the inflammatory tumor micro-environment provide 
immune escape via M2-like macrophages, but also through increased tumorigenesis and 
cell growth. The activation of NF-κB promotes expression of anti-apoptotic proteins such 
as Bcl-XL, BFL (another Bcl-2 family member), and growth arrest and DNA-damage-
inducible 45β (GADD45β)160. 
Another means of immune evasion occurs via the upregulation of checkpoint 
inhibitors, such as PD-L1, CD80 and other B7 family members. These immunological 
regulators provide tumors with T cell tolerance; for example, CD80/CTLA-4 and 
CD80/CD28 activity induce T cell anergy161,162, whereas PD-L1/PD-1 activity potentiates 
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T cell exhaustion163. In specific cancer types, such as epidermal growth factor receptor 
(EGFR)-driven NSCLC, upregulation of PD-L1 has been directly linked to potentiating 
immune escape164. Oncogenes provide one potential means of upregulating these 
checkpoint inhibitors, such as the myelocytoma oncogene (MYC) driving increased 
expression of CD47 and PD-L1165. Other studies have implicated exogenous 
pharmaceutical agents, such as resveratrol and piceatannol, in upregulating PD-L1 
expression in colorectal and breast cancer cells via NF-κB signaling166. 
4.2 Treatment Implications  
The multiplicity of effects of apoptosis in the tumor microenvironment have profound 
implications for treatment. Those cells in the tumor microenvironment which are 
sensitive to chemotherapies and do undergo apoptosis may stimulate proliferation of 
neighboring tumor cells through cytokine release and AiP. As suggested by Fogarty & 
Bergmann167, there could exist a link between chemotherapeutics and the release of 
PGE2, release of VEGF and subsequent angiogenesis, and/or death of vascular 
endothelial cells in the tumor microenvironment. All of these are possible mechanisms by 
which AiP could be induced, and if following administration of chemotherapies, could 
result in prolific and chemo-resistant tumors. 
However, high levels of apoptosis in the tumor microenvironment may reveal 
novel, effective targets for cancer therapy. If tumors have adopted PS-PSR recognition 
and other as a means of immune suppression, inhibiting this interaction would prevent 
efferocytosis and the release of anti-inflammatory cytokines. Similarly, for cancers over-
expressing checkpoint inhibitors such as members of the B7 family (i.e. PD-L1, CD80), it 
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should be possible to block this pathway to prevent T cell exhaustion/anergy. These 
therapies would drive an appropriate immune response to the tumors and enable the body 
to clear the cells effectively.  
 
DISCUSSION 
Cancer is defined by an imbalance of cellular proliferation relative to cell death, but that 
does not inherently mean tumor cells are not dying. Imagine a solid tumor as a sphere of 
cells; while the innermost cells may lack proper vascularization and die by ischemic 
necrosis, those in the circumferential perimeter act as a shield from immune interaction. 
These cells are immune-susceptible, as they are exposed to interact with professional 
phagocytes and T cells. However, by co-opting an apoptotic phenotype and undergoing 
efferocytotic engulfment, these cells generate immunosuppressive signals in the 
immediate environment. This tricks the immune system into believing that it has 
appropriately cleared the apoptotic cells, remaining blind to the growing tumor 
underneath. 
This theory is further complicated by current methods of treatment. 
Chemotherapies which induce even greater levels of apoptosis may outweigh 
proliferation to the point of suppressing tumor growth and diminishing tumor size. 
However, while the intention of triggering apoptotic death may be to spare patients from 
a full immune response, this may be worsening the situation. One mechanism for this 
would be through AiP; as high levels of apoptosis may send signals to the surrounding 
environment to “re-generate” lost tissue, particularly once chemo- or radiotherapy has 
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ceased. This phenomenon could be creating opportunities for tumor recurrence and/or 
chemoresistance. 
By discussing the complexities of the interplay between regulated cell death (i.e. 
apoptosis, necroptosis) and tumor cell growth and development, this thesis offers an 
introductory glance into how this phenomenon could manifest.  
  
42 
LIST OF JOURNAL ABBREVIATIONS 
Am J Pathol. American Journal of Pathology 
Arthritis Rheum. Arthritis & Rheumatology 
Br J Cancer British Journal of Cancer 
Brain Res. Brain Research 
Cell Bio Int. Cell Biology International 
Cell Death Differ. Cell Death and Differentiation 
Cell Mol Life Sci. Cellular and Molecular Life Science 
Cell Tissue Res.  Cell Tissue Research 
Curr Biol. Current Biology 
Curr Med Chem. Current Medicinal Chemistry 





Eur J Cancer Prev. 









European Journal of Cancer Prevention 
Experimental Cell Research 
Frontiers in Immunology 
Genes & Development 
Immunologic Research 
Int J Cancer International Journal of Cancer 
 
43 
Int J Oncol. International Journal of Oncology 
J Am Acad Dermatol. Journal of the American Academy of Dermatology 
J Cell Bio. Journal of Cell Biology 
J Exp Med. Journal of Experimental Medicine 
J Immunol. Journal of Immunology 
J Innate Immun. Journal of Innate Immunity 
J Insect Physiol. Journal of Insect Physiology 
J Microsc Ultrastruct Journal of Microscopy and Ultrastructure 
J Neurosci. Journal of Neuroscience 
J Pathol Journal of Pathology 
J Vasc Surg Journal of Vascular Surgery 
JIOH Journal of International Oral Health 
Mol Cell Biochem Molecular and Cellular Biochemistry 
Mol Cell Neurosci. Molecular and Cellular Neuroscience 
Mol Cell. Molecular Cell 
Nat Chem Biol. Nature Chemical Biology 
Nat Med. Nature Medicine 
Nat Rev Immunol. Nature Reviews Immunology 
NEJM  New England Journal of Medicine 
PLoS Biol. PLoS Biology 
PLoS Genet. PLoS Genetics 
PNAS Proceedings of the National Academy of Sciences of the United 
States of America  
 
44 
Radiol Res Pract. Radiology Research and Practice 
Respir Res. Respiratory Research 
Sci Rep. Scientific Reports 
Sci Signal. Science Signaling 
Semin Cancer Biol. Seminars in Cancer Biolgy 






1.  Cancer Facts & Figures 2020 | American Cancer Society. Accessed June 8, 2020. 
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-
figures/cancer-facts-figures-2020.html 
2.  Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol Off J Am Soc Clin Oncol. 
1999;17(9):2941-2953. doi:10.1200/JCO.1999.17.9.2941 
3.  Lockshin RA, Williams CM. Programmed cell death—I. Cytology of degeneration in 
the intersegmental muscles of the Pernyi silkmoth. J Insect Physiol. 1965;11(2):123-
133. doi:10.1016/0022-1910(65)90099-5 
4.  Tata JR. Requirement for RNA and protein synthesis for induced regression of the 
tadpole tail in organ culture. Dev Biol. 1966;13(1):77-94. doi:10.1016/0012-
1606(66)90050-9 
5.  Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A Basic Biological Phenomenon with 
Wide-ranging Implications in Tissue Kinetics. Br J Cancer. 1972;26(4):239-257. 
6.  Häcker G. The morphology of apoptosis. Cell Tissue Res. 2000;301(1):5-17. 
doi:10.1007/s004410000193 
7.  Jr CAJ, Travers P, Walport M, et al. Immunobiology. 5th ed. Garland Science; 2001. 
8.  Purdue Cytometry CD ROM Volume 4. Accessed June 27, 2020. 
http://www.cyto.purdue.edu/cdroms/cyto3/8/pucl/vol4info/cdv4.htm 
9.  Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. 
elegans. Cell. 1986;44(6):817-829. doi:10.1016/0092-8674(86)90004-8 
10.  Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene 
ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. 
Cell. 1993;75(4):641-652. doi:10.1016/0092-8674(93)90485-9 
11.  Galluzzi L, Joza N, Tasdemir E, et al. No death without life: vital functions of 
apoptotic effectors. Cell Death Differ. 2008;15(7):1113-1123. 
doi:10.1038/cdd.2008.28 
12.  Lamkanfi M, Festjens N, Declercq W, Berghe TV, Vandenabeele P. Caspases in cell 




13.  Feinstein-Rotkopf Y, Arama E. Can’t live without them, can live with them: roles of 
caspases during vital cellular processes. Apoptosis. 2009;14(8):980-995. 
doi:10.1007/s10495-009-0346-6 
14.  Tummers B, Green DR. Caspase-8: regulating life and death. Immunol Rev. 
2017;277(1):76-89. doi:10.1111/imr.12541 
15.  Fritsch M, Günther SD, Schwarzer R, et al. Caspase-8 is the molecular switch for 
apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683-687. 
doi:10.1038/s41586-019-1770-6 
16.  Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA 
degradation during apoptosis. Nature. 1998;391(6662):96-99. doi:10.1038/34214 
17.  Opferman JT, Kothari A. Anti-apoptotic BCL-2 family members in development. Cell 
Death Differ. 2018;25(1):37-45. doi:10.1038/cdd.2017.170 
18.  Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic 
cascade activates BID, which oligomerizes BAK or BAX into pores that result in the 
release of cytochrome c. Cell Death Differ. 2000;7(12):1166-1173. 
doi:10.1038/sj.cdd.4400783 
19.  Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a Human Protein Homologous 
to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of 
Caspase-3. Cell. 1997;90(3):405-413. doi:10.1016/S0092-8674(00)80501-2 
20.  Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-Dependent Formation 
of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade. Cell. 
1997;91(4):479-489. doi:10.1016/S0092-8674(00)80434-1 
21.  Du C, Fang M, Li Y, Li L, Wang X. Smac, a Mitochondrial Protein that Promotes 
Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition. Cell. 
2000;102(1):33-42. doi:10.1016/S0092-8674(00)00008-8 
22.  Vande Walle L, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease 
HtrA2/Omi: an overview. Cell Death Differ. 2008;15(3):453-460. 
doi:10.1038/sj.cdd.4402291 
23.  Larisch S, Yi Y, Lotan R, et al. A novel mitochondrial septin-like protein, ARTS, 




24.  Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and 
immune homeostasis. Nat Rev Immunol. 2006;6(12):940-952. doi:10.1038/nri1983 
25.  Lieberman J, Fan Z. Nuclear war: the granzyme A-bomb. Curr Opin Immunol. 
2003;15(5):553-559. doi:10.1016/S0952-7915(03)00108-0 
26.  Sutton VR, Davis JE, Cancilla M, et al. Initiation of Apoptosis by Granzyme B 
Requires Direct Cleavage of Bid, but Not Direct Granzyme B–Mediated Caspase 
Activation. J Exp Med. 2000;192(10):1403-1414. doi:10.1084/jem.192.10.1403 
27.  Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that 
regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 
1993;4(6):327-332. 
28.  Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric 
partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 
1995;80(2):285-291. doi:10.1016/0092-8674(95)90411-5 
29.  Salomons GS, Brady HJM, Verwijs‐Janssen M, et al. The Baxα:Bcl-2 ratio modulates 
the response to dexamethasone in leukaemic cells and is highly variable in 
childhood acute leukaemia. Int J Cancer. 1997;71(6):959-965. 
doi:10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X 
30.  Boumela I, Assou S, Haouzi D, Déchaud H, Ait-Ahmed O, Hamamah S. 
Developmental Regulated Expression of Anti- and Pro-Apoptotic BCL-2 Family 
Genes During Human Early Embryonic Development. Curr Med Chem. 
2014;21(11):1361-1369. 
31.  Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results 
in peri-implantation embryonic lethality. :6. 
32.  Fogarty LC, Flemmer RT, Geizer BA, et al. Mcl-1 and Bcl-xL are essential for survival 
of the developing nervous system. Cell Death Differ. 2019;26(8):1501-1515. 
doi:10.1038/s41418-018-0225-1 
33.  Germain M, Nguyen AP, Grand JNL, et al. MCL‐1 is a stress sensor that regulates 
autophagy in a developmentally regulated manner. EMBO J. 2011;30(2):395-407. 
doi:10.1038/emboj.2010.327 
34.  Harder JM, Ding Q, Fernandes KA, Cherry JD, Gan L, Libby RT. BCL2L1 (BCL-X) 




35.  Nakamura A, Swahari V, Plestant C, et al. Bcl-xL Is Essential for the Survival and 
Function of Differentiated Neurons in the Cortex That Control Complex Behaviors. J 
Neurosci. 2016;36(20):5448-5461. doi:10.1523/JNEUROSCI.4247-15.2016 
36.  Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Gruss P. Apaf1 (CED-4 Homolog) 
Regulates Programmed Cell Death in Mammalian Development. Cell. 
1998;94(6):727-737. doi:10.1016/S0092-8674(00)81732-8 
37.  D’Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: beyond 
apoptosis. Trends Neurosci. 2012;35(11):700-709. doi:10.1016/j.tins.2012.06.004 
38.  Elliott MR, Koster KM, Murphy PS. Efferocytosis Signaling in the Regulation of 
Macrophage Inflammatory Responses. J Immunol. 2017;198(4):1387-1394. 
doi:10.4049/jimmunol.1601520 
39.  Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development 
and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 
2003;426(6967):671-676. doi:10.1038/nature02067 
40.  Dzhagalov I, Dunkle A, He Y-W. The Anti-Apoptotic Bcl-2 Family Member Mcl-1 
Promotes T Lymphocyte Survival at Multiple Stages. J Immunol. 2008;181(1):521-
528. doi:10.4049/jimmunol.181.1.521 
41.  Lee D-H, Kim C, Zhang L, Lee YJ. Role of p53, PUMA, and Bax in wogonin-induced 
apoptosis in human cancer cells. Biochem Pharmacol. 2008;75(10):2020-2033. 
doi:10.1016/j.bcp.2008.02.023 
42.  Ma A, Pena JC, Chang B, et al. Bclx regulates the survival of double-positive 
thymocytes. Proc Natl Acad Sci. 1995;92(11):4763-4767. 
doi:10.1073/pnas.92.11.4763 
43.  Fuchs Y, Steller H. Programmed Cell Death in Animal Development and Disease. 
Cell. 2011;147(4):742-758. doi:10.1016/j.cell.2011.10.033 
44.  Proskuryakov SY a, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of 
programmed cell death? Exp Cell Res. 2003;283(1):1-16. doi:10.1016/S0014-
4827(02)00027-7 
45.  Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic 




46.  Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. 
Curr Opin Cell Biol. 2004;16(6):663-669. doi:10.1016/j.ceb.2004.09.011 
47.  Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the 
mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the 
inner mitochondrial membrane. J Bioenerg Biomembr. 1994;26(5):509-517. 
doi:10.1007/BF00762735 
48.  Marchetti P, Hirsch T, Zamzami N, et al. Mitochondrial permeability transition 
triggers lymphocyte apoptosis. J Immunol Baltim Md 1950. 1996;157(11):4830-
4836. 
49.  Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for 
mitochondrial permeability transition in cell death. Nature. 2005;434(7033):658-
662. doi:10.1038/nature03434 
50.  Halestrap AP, Connern CP, Griffiths EJ, Kerr PM. Cyclosporin A binding to 
mitochondrial cyclophilin inhibits the permeability transition pore and protects 
hearts from ischaemia/reperfusion injury. Mol Cell Biochem. 1997;174(1-2):167-
172. 
51.  Pottecher J, Guillot M, Belaidi E, et al. Cyclosporine A normalizes mitochondrial 
coupling, reactive oxygen species production, and inflammation and partially 
restores skeletal muscle maximal oxidative capacity in experimental aortic cross-
clamping. J Vasc Surg. 2013;57(4):1100-1108.e2. doi:10.1016/j.jvs.2012.09.020 
52.  Karch J, Kwong JQ, Burr AR, et al. Bax and Bak function as the outer membrane 
component of the mitochondrial permeability pore in regulating necrotic cell death 
in mice. eLife. 2013;2:e00772. doi:10.7554/eLife.00772 
53.  Adigun R, Basit H, Murray J. Necrosis, Cell (Liquefactive, Coagulative, Caseous, Fat, 
Fibrinoid, and Gangrenous). In: StatPearls. StatPearls Publishing; 2020. Accessed 
May 22, 2020. http://www.ncbi.nlm.nih.gov/books/NBK430935/ 
54.  Tonnus W, Meyer C, Paliege A, et al. The pathological features of regulated 
necrosis. J Pathol. 2019;247(5):697-707. doi:10.1002/path.5248 
55.  Ehlers S, Schaible UE. The Granuloma in Tuberculosis: Dynamics of a Host–
Pathogen Collusion. Front Immunol. 2013;3. doi:10.3389/fimmu.2012.00411 
56.  Kerridge WD, Kryvenko ON, Thompson A, Shah BA. Fat Necrosis of the Breast: A 
Pictorial Review of the Mammographic, Ultrasound, CT, and MRI Findings with 
 
50 
Histopathologic Correlation. Radiol Res Pract. 2015;2015. 
doi:10.1155/2015/613139 
57.  Arseculeratne SN, Panabokke RG, Navaratnam C. Pathogenesis of necrotising 
enteritis with special reference to intestinal hypersensitivity reactions. Gut. 
1980;21(4):265-278. doi:10.1136/gut.21.4.265 
58.  Rachid B, Rabelo-Santos M, Mansour E, de Lima Zollner R, Velloso LA. Type III 
hypersensitivity to insulin leading to leukocytoclastic vasculitis. Diabetes Res Clin 
Pract. 2010;89(3):e39-e40. doi:10.1016/j.diabres.2010.05.019 
59.  Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 Necrosome Forms a Functional 
Amyloid Signaling Complex Required for Programmed Necrosis. Cell. 
2012;150(2):339-350. doi:10.1016/j.cell.2012.06.019 
60.  D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and 
autophagy. Cell Biol Int. 2019;43(6):582-592. doi:10.1002/cbin.11137 
61.  Wang H, Sun L, Su L, et al. Mixed Lineage Kinase Domain-like Protein MLKL Causes 
Necrotic Membrane Disruption upon Phosphorylation by RIP3. Mol Cell. 
2014;54(1):133-146. doi:10.1016/j.molcel.2014.03.003 
62.  Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the 
host response. Nature. 2006;442(7098):39-44. doi:10.1038/nature04946 
63.  Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and 
an activator of innate immune response. Nature. 2007;448(7152):501-505. 
doi:10.1038/nature06013 
64.  Rebsamen M, Heinz LX, Meylan E, et al. DAI/ZBP1 recruits RIP1 and RIP3 through 
RIP homotypic interaction motifs to activate NF‐κB. EMBO Rep. 2009;10(8):916-
922. doi:10.1038/embor.2009.109 
65.  Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: Is immunity the second 
function of chromatin? J Cell Biol. 2012;198(5):773-783. 
doi:10.1083/jcb.201203170 
66.  Wartha F, Henriques-Normark B. ETosis: A Novel Cell Death Pathway. Sci Signal. 
2008;1(21):pe25-pe25. doi:10.1126/stke.121pe25 
67.  Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by 




68.  Morshed M, Hlushchuk R, Simon D, et al. NADPH Oxidase–Independent Formation 
of Extracellular DNA Traps by Basophils. J Immunol. 2014;192(11):5314-5323. 
doi:10.4049/jimmunol.1303418 
69.  Neeli I, Dwivedi N, Khan S, Radic M. Regulation of Extracellular Chromatin Release 
from Neutrophils. J Innate Immun. 2009;1(3):194-201. doi:10.1159/000206974 
70.  Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular 
traps to ensnare bacteria in septic blood. Nat Med. 2007;13(4):463-469. 
doi:10.1038/nm1565 
71.  Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil 
extracellular traps. J Cell Biol. 2007;176(2):231-241. doi:10.1083/jcb.200606027 
72.  Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene 
therapy in CGD controls aspergillosis. Blood. 2009;114(13):2619-2622. 
doi:10.1182/blood-2009-05-221606 
73.  Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death 
Differ. 2018;25(3):486-541. doi:10.1038/s41418-017-0012-4 
74.  Wong SL, Demers M, Martinod K, et al. Diabetes primes neutrophils to undergo 
NETosis which severely impairs wound healing. Nat Med. 2015;21(7):815-819. 
doi:10.1038/nm.3887 
75.  Cools-Lartigue J, Spicer J, Najmeh S, Ferri L. Neutrophil extracellular traps in cancer 
progression. Cell Mol Life Sci. 2014;71(21):4179-4194. doi:10.1007/s00018-014-
1683-3 
76.  Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An Iron-Dependent Form 
of Non-Apoptotic Cell Death. Cell. 2012;149(5):1060-1072. 
doi:10.1016/j.cell.2012.03.042 
77.  Xie Y, Hou W, Song X, et al. Ferroptosis: process and function. Cell Death Differ. 
2016;23(3):369-379. doi:10.1038/cdd.2015.158 
78.  Kıvrak EG, Yurt KK, Kaplan AA, Alkan I, Altun G. Effects of electromagnetic fields 
exposure on the antioxidant defense system. J Microsc Ultrastruct. 2017;5(4):167-
176. doi:10.1016/j.jmau.2017.07.003 
79.  Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of Ferroptotic Cancer Cell 
Death by GPX4. Cell. 2014;156(0):317-331. doi:10.1016/j.cell.2013.12.010 
 
52 
80.  Kagan VE, Mao G, Qu F, et al. Oxidized Arachidonic/Adrenic 
Phosphatidylethanolamines Navigate Cells to Ferroptosis. Nat Chem Biol. 
2017;13(1):81-90. doi:10.1038/nchembio.2238 
81.  Mizushima N, Komatsu M. Autophagy: Renovation of Cells and Tissues. Cell. 
2011;147(4):728-741. doi:10.1016/j.cell.2011.10.026 
82.  Ndoye A, Weeraratna AT. Autophagy- An emerging target for melanoma therapy. 
F1000Research. 2016;5. doi:10.12688/f1000research.8347.1 
83.  Cuervo AM. Autophagy: Many paths to the same end. Mol Cell Biochem. 
2004;263(1/2):55-72. doi:10.1023/B:MCBI.0000041848.57020.57 
84.  Li W, Li J, Bao J. Microautophagy: lesser-known self-eating. Cell Mol Life Sci. 
2012;69(7):1125-1136. doi:10.1007/s00018-011-0865-5 
85.  Kaushik S, Cuervo AM. The coming of age of chaperone-mediated autophagy. Nat 
Rev Mol Cell Biol. 2018;19(6):365-381. doi:10.1038/s41580-018-0001-6 
86.  Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death 
Differ. 2018;25(3):486-541. doi:10.1038/s41418-017-0012-4 
87.  Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. 
Nat Rev Microbiol. 2009;7(2):99-109. doi:10.1038/nrmicro2070 
88.  Shi J, Gao W, Shao F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell 
Death. Trends Biochem Sci. 2017;42(4):245-254. doi:10.1016/j.tibs.2016.10.004 
89.  Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr Biol. 
2001;11(19):R795-R805. doi:10.1016/S0960-9822(01)00474-2 
90.  Parnaik R, Raff MC, Scholes J. Differences between the clearance of apoptotic cells 
by professional and non-professional phagocytes. Curr Biol. 2000;10(14):857-860. 
doi:10.1016/S0960-9822(00)00598-4 
91.  Franc NC. Phagocytosis of apoptotic cells in mammals, caenorhabditis elegans and 
Drosophila melanogaster: molecular mechanisms and physiological consequences. 
Front Biosci J Virtual Libr. 2002;7:d1298-1313. 




93.  Zhou Z, Hartwieg E, Horvitz HR. CED-1 Is a Transmembrane Receptor that Mediates 
Cell Corpse Engulfment in C. elegans. Cell. 2001;104(1):43-56. doi:10.1016/S0092-
8674(01)00190-8 
94.  Wu YC, Horvitz HR. The C. elegans cell corpse engulfment gene ced-7 encodes a 
protein similar to ABC transporters. Cell. 1998;93(6):951-960. doi:10.1016/s0092-
8674(00)81201-5 
95.  Liu QA, Hengartner MO. Candidate adaptor protein CED-6 promotes the 
engulfment of apoptotic cells in C. elegans. Cell. 1998;93(6):961-972. 
doi:10.1016/s0092-8674(00)81202-7 
96.  Yu X, Lu N, Zhou Z. Phagocytic receptor CED-1 initiates a signaling pathway for 
degrading engulfed apoptotic cells. PLoS Biol. 2008;6(3):e61. 
doi:10.1371/journal.pbio.0060061 
97.  Reddien PW, Horvitz HR. CED-2/CrkII and CED-10/Rac control phagocytosis and cell 
migration in Caenorhabditis elegans. Nat Cell Biol. 2000;2(3):131-136. 
doi:10.1038/35004000 
98.  Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. Xk-Related Protein 8 and 
CED-8 Promote Phosphatidylserine Exposure in Apoptotic Cells. Science. 
2013;341(6144):403-406. doi:10.1126/science.1236758 
99.  Su HP, Brugnera E, Van Criekinge W, et al. Identification and characterization of a 
dimerization domain in CED-6, an adapter protein involved in engulfment of 
apoptotic cells. J Biol Chem. 2000;275(13):9542-9549. doi:10.1074/jbc.275.13.9542 
100.  Su HP, Nakada-Tsukui K, Tosello-Trampont A-C, et al. Interaction of CED-6/GULP, 
an Adapter Protein Involved in Engulfment of Apoptotic Cells with CED-1 and 
CD91/Low Density Lipoprotein Receptor-related Protein (LRP). J Biol Chem. 
2002;277(14):11772-11779. doi:10.1074/jbc.M109336200 
101.  Santoso CS, Meehan TL, Peterson JS, Cedano TM, Turlo CV, McCall K. The ABC 
Transporter Eato Promotes Cell Clearance in the Drosophila melanogaster Ovary. 
G3 Bethesda Md. 2018;8(3):833-843. doi:10.1534/g3.117.300427 
102.  Nolan KM, Barrett K, Lu Y, Hu K-Q, Vincent S, Settleman J. Myoblast city, the 
Drosophila homolog of DOCK180/CED-5, is required in a Rac signaling pathway 
utilized for multiple developmental processes. Genes Dev. 1998;12(21):3337-3342. 
 
54 
103.  Wu Y-C, Tsai M-C, Cheng L-C, Chou C-J, Weng N-Y. C. elegans CED-12 Acts in the 
Conserved CrkII/DOCK180/Rac Pathway to Control Cell Migration and Cell Corpse 
Engulfment. Dev Cell. 2001;1(4):491-502. doi:10.1016/S1534-5807(01)00056-9 
104.  Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. 
Nat Immunol. 2015;16(9):907-917. doi:10.1038/ni.3253 
105.  Park D, Tosello-Trampont A-C, Elliott MR, et al. BAI1 is an engulfment receptor for 
apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature. 
2007;450(7168):430-434. doi:10.1038/nature06329 
106.  Wu Y, Singh S, Georgescu M-M, Birge RB. A role for Mer tyrosine kinase in αvβ5 
integrin-mediated phagocytosis of apoptotic cells. J Cell Sci. 2005;118(3):539-553. 
doi:10.1242/jcs.01632 
107.  Kumar S, Calianese D, Birge RB. Efferocytosis of dying cells differentially modulate 
immunological outcomes in tumor microenvironment. Immunol Rev. 
2017;280(1):149-164. doi:10.1111/imr.12587 
108.  Baumann I, Kolowos W, Voll RE, et al. Impaired uptake of apoptotic cells into 
tingible body macrophages in germinal centers of patients with systemic lupus 
erythematosus. Arthritis Rheum. 2002;46(1):191-201. doi:10.1002/1529-
0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K 
109.  Lehmann P, Hölzle E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin 
lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 
1990;22(2 Pt 1):181-187. doi:10.1016/0190-9622(90)70020-i 
110.  Muñoz LE, Janko C, Grossmayer GE, et al. Remnants of secondarily necrotic cells 
fuel inflammation in systemic lupus erythematosus. Arthritis Rheum. 
2009;60(6):1733-1742. doi:10.1002/art.24535 
111.  Asano K, Miwa M, Miwa K, et al. Masking of phosphatidylserine inhibits apoptotic 
cell engulfment and induces autoantibody production in mice. J Exp Med. 
2004;200(4):459-467. doi:10.1084/jem.20040342 
112.  Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D. Accelerated Fas-
mediated apoptosis of monocytes and maturing macrophages from patients with 
systemic lupus erythematosus: relevance to in vitro impairment of interaction with 




113.  Rothlin CV, Ghosh S, Zuniga EI, Oldstone MBA, Lemke G. TAM Receptors Are 
Pleiotropic Inhibitors of the Innate Immune Response. Cell. 2007;131(6):1124-
1136. doi:10.1016/j.cell.2007.10.034 
114.  Carrera Silva EA, Chan PY, Joannas L, et al. T cell-derived protein S engages TAM 
receptor signaling in dendritic cells to control the magnitude of the immune 
response. Immunity. 2013;39(1):160-170. doi:10.1016/j.immuni.2013.06.010 
115.  Sen P, Wallet MA, Yi Z, et al. Apoptotic cells induce Mer tyrosine kinase-dependent 
blockade of NF-kappaB activation in dendritic cells. Blood. 2007;109(2):653-660. 
doi:10.1182/blood-2006-04-017368 
116.  Santiago C, Ballesteros A, Tami C, Martínez-Muñoz L, Kaplan GG, Casasnovas JM. 
Structures of T Cell Immunoglobulin Mucin Receptors 1 and 2 Reveal Mechanisms 
for Regulation of Immune Responses by the TIM Receptor Family. Immunity. 
2007;26(3):299-310. doi:10.1016/j.immuni.2007.01.014 
117.  Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid-
mediated innate immune responses through interactions between the receptor 
TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832-842. 
doi:10.1038/ni.2376 
118.  Hoehn HJ, Kress Y, Sohn A, Brosnan CF, Bourdon S, Shafit-Zagardo B. Axl-/- mice 
have delayed recovery and prolonged axonal damage following cuprizone toxicity. 
Brain Res. 2008;1240:1-11. doi:10.1016/j.brainres.2008.08.076 
119.  Weinger JG, Brosnan CF, Loudig O, et al. Loss of the receptor tyrosine kinase Axl 
leads to enhanced inflammation in the CNS and delayed removal of myelin debris 
during Experimental Autoimmune Encephalomyelitis. J Neuroinflammation. 
2011;8:49. doi:10.1186/1742-2094-8-49 
120.  Binder MD, Cate HS, Prieto AL, et al. Gas6 Deficiency Increases Oligodendrocyte 
Loss and Microglial Activation in Response to Cuprizone-Induced Demyelination. J 
Neurosci. 2008;28(20):5195-5206. doi:10.1523/JNEUROSCI.1180-08.2008 
121.  Tsiperson V, Li X, Schwartz GJ, Raine CS, Shafit-Zagardo B. GAS6 Enhances Repair 
Following Cuprizone-Induced Demyelination. PLoS ONE. 2010;5(12). 
doi:10.1371/journal.pone.0015748 
122.  Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-




123.  Lee CS, Penberthy KK, Wheeler KM, et al. Boosting Apoptotic Cell Clearance by 
Colonic Epithelial Cells Attenuates Inflammation In Vivo. Immunity. 2016;44(4):807-
820. doi:10.1016/j.immuni.2016.02.005 
124.  Serhan CN. Resolution phase of inflammation: novel endogenous anti-
inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 
2007;25:101-137. doi:10.1146/annurev.immunol.25.022106.141647 
125.  Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory 
and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8(5):349-361. 
doi:10.1038/nri2294 
126.  Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching 
during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612-619. 
doi:10.1038/89759 
127.  Howangyin K-Y, Zlatanova I, Pinto C, et al. Myeloid-Epithelial-Reproductive 
Receptor Tyrosine Kinase and Milk Fat Globule Epidermal Growth Factor 8 
Coordinately Improve Remodeling After Myocardial Infarction via Local Delivery of 
Vascular Endothelial Growth Factor. Circulation. 2016;133(9):826-839. 
doi:10.1161/CIRCULATIONAHA.115.020857 
128.  Noguera A, Gomez C, Faner R, et al. An investigation of the resolution of 
inflammation (catabasis) in COPD. Respir Res. 2012;13(1):101. doi:10.1186/1465-
9921-13-101 
129.  Gong D, Shi W, Yi S, Chen H, Groffen J, Heisterkamp N. TGFβ signaling plays a 
critical role in promoting alternative macrophage activation. BMC Immunol. 
2012;13(1):31. doi:10.1186/1471-2172-13-31 
130.  Wynn TA, Chawla A, Pollard JW. Origins and Hallmarks of Macrophages: 
Development, Homeostasis, and Disease. Nature. 2013;496(7446):445-455. 
doi:10.1038/nature12034 
131.  Kang J-W, Lee S-M. Resolvin D1 protects the liver from ischemia/reperfusion injury 
by enhancing M2 macrophage polarization and efferocytosis. Biochim Biophys Acta 
BBA - Mol Cell Biol Lipids. 2016;1861(9, Part A):1025-1035. 
doi:10.1016/j.bbalip.2016.06.002 
132.  Das A, Ganesh K, Khanna S, Sen CK, Roy S. Engulfment of apoptotic cells by 
macrophages: a role of microRNA-21 in the resolution of wound inflammation. J 
Immunol Baltim Md 1950. 2014;192(3):1120-1129. doi:10.4049/jimmunol.1300613 
 
57 
133.  Das A, Abas M, Biswas N, et al. A Modified Collagen Dressing Induces Transition of 
Inflammatory to Reparative Phenotype of Wound Macrophages. Sci Rep. 2019;9. 
doi:10.1038/s41598-019-49435-z 
134.  Huh JR, Guo M, Hay BA. Compensatory proliferation induced by cell death in the 
Drosophila wing disc requires activity of the apical cell death caspase Dronc in a 
nonapoptotic role. Curr Biol CB. 2004;14(14):1262-1266. 
doi:10.1016/j.cub.2004.06.015 
135.  Diwanji N, Bergmann A. Two Sides of the Same Coin – Compensatory Proliferation 
in Regeneration and Cancer. In: Deng W-M, ed. The Drosophila Model in Cancer. 
Advances in Experimental Medicine and Biology. Springer International Publishing; 
2019:65-85. doi:10.1007/978-3-030-23629-8_4 
136.  Amcheslavsky A, Wang S, Fogarty CE, Lindblad JL, Fan Y, Bergmann A. Plasma 
Membrane Localization of Apoptotic Caspases for Non-apoptotic Functions. Dev 
Cell. 2018;45(4):450-464.e3. doi:10.1016/j.devcel.2018.04.020 
137.  Shlevkov E, Morata G. A dp53/JNK-dependant feedback amplification loop is 
essential for the apoptotic response to stress in Drosophila. Cell Death Differ. 
2012;19(3):451-460. doi:10.1038/cdd.2011.113 
138.  Muzzopappa M, Murcia L, Milán M. Feedback amplification loop drives malignant 
growth in epithelial tissues. Proc Natl Acad Sci. 2017;114(35):E7291-E7300. 
doi:10.1073/pnas.1701791114 
139.  Ryoo HD, Gorenc T, Steller H. Apoptotic Cells Can Induce Compensatory Cell 
Proliferation through the JNK and the Wingless Signaling Pathways. Dev Cell. 
2004;7(4):491-501. doi:10.1016/j.devcel.2004.08.019 
140.  Perez-Garijo A, Shlevkov E, Morata G. The role of Dpp and Wg in compensatory 
proliferation and in the formation of hyperplastic overgrowths caused by apoptotic 
cells in the Drosophila wing disc. Development. 2009;136(7):1169-1177. 
doi:10.1242/dev.034017 
141.  Santabárbara-Ruiz P, López-Santillán M, Martínez-Rodríguez I, et al. ROS-Induced 
JNK and p38 Signaling Is Required for Unpaired Cytokine Activation during 
Drosophila Regeneration. PLoS Genet. 2015;11(10). 
doi:10.1371/journal.pgen.1005595 
142.  Santabárbara-Ruiz P, Esteban-Collado J, Pérez L, et al. Ask1 and Akt act 




143.  Meserve JH, Duronio RJ. Scalloped and Yorkie are required for cell cycle re-entry of 
quiescent cells after tissue damage. Development. 2015;142(16):2740-2751. 
doi:10.1242/dev.119339 
144.  Leoncini L, Del Vecchio MT, Megha T, et al. Correlations Between Apoptotic and 
Proliferative Indices in Malignant Non-Hodgkin’s Lymphomas. Am J Pathol. 
1993;142(3):755-763. 
145.  Liu W, Li J, Song Y-S, Li Y, Jia Y-H, Zhao H-D. Cdk5 links with DNA damage response 
and cancer. Mol Cancer. 2017;16(1):60. doi:10.1186/s12943-017-0611-1 
146.  Tanaka F, Kawano Y, Li M, et al. Prognostic Significance of Apoptotic Index in 
Completely Resected Non–Small-Cell Lung Cancer. J Clin Oncol. 1999;17(9):2728-
2728. doi:10.1200/JCO.1999.17.9.2728 
147.  Kyrylkova K, Kyryachenko S, Leid M, Kioussi C. Detection of apoptosis by TUNEL 
assay. Methods Mol Biol Clifton NJ. 2012;887:41-47. doi:10.1007/978-1-61779-860-
3_5 
148.  Dworakowska D, Jassem E, Jassem J, et al. Clinical significance of apoptotic index in 
non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 
protein expression. J Cancer Res Clin Oncol. 2005;131(9):617-623. 
doi:10.1007/s00432-005-0010-7 
149.  Heatley MK. Association between the apoptotic index and established prognostic 
parameters in endometrial adenocarcinoma. Histopathology. 1995;27(5):469-472. 
doi:10.1111/j.1365-2559.1995.tb00312.x 
150.  Sun B, Sun Y, Wang J, Zhao X, Wang X, Hao X. Extent, relationship and prognostic 
significance of apoptosis and cell proliferation in synovial sarcoma. Eur J Cancer 
Prev. 2006;15(3):258–265. doi:10.1097/01.cej.0000198896.02185.68 
151.  Stapleton AM, Zbell P, Kattan MW, et al. Assessment of the biologic markers p53, 
Ki-67, and apoptotic index as predictive indicators of prostate carcinoma 
recurrence after surgery. Cancer. 1998;82(1):168-175. doi:10.1002/(sici)1097-
0142(19980101)82:1<168::aid-cncr21>3.0.co;2-# 
152.  Viswanathan V, Juluri R, Goel S, Madan J, Mitra SK, Gopalakrishnan D. Apoptotic 
Index and Proliferative Index in Premalignant and Malignant Squamous Cell Lesions 
of the Oral Cavity. J Int Oral Health JIOH. 2015;7(1):40-43. 
 
59 
153.  Zhang GJ, Kimijima I, Abe R, et al. Apoptotic index correlates to bcl-2 and p53 
protein expression, histological grade and prognosis in invasive breast cancers. 
Anticancer Res. 1998;18(3B):1989-1998. 
154.  Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard 
prognostic factors and prognosis. J Pathol. 1994;173(4):333-339. 
doi:10.1002/path.1711730408 
155.  Dvorak HF. Tumors: Wounds That Do Not Heal. N Engl J Med. 1986;315(26):1650-
1659. doi:10.1056/NEJM198612253152606 
156.  Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages 
(TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 
2009;86(5):1065-1073. doi:10.1189/jlb.0609385 
157.  Comito G, Giannoni E, Segura CP, et al. Cancer-associated fibroblasts and M2-
polarized macrophages synergize during prostate carcinoma progression. 
Oncogene. 2014;33(19):2423-2431. doi:10.1038/onc.2013.191 
158.  Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-
environment in tumor progression: The role of tumor-associated macrophages. Crit 
Rev Oncol Hematol. 2008;66(1):1-9. doi:10.1016/j.critrevonc.2007.07.004 
159.  Yang M, Liu J, Piao C, Shao J, Du J. ICAM-1 suppresses tumor metastasis by 
inhibiting macrophage M2 polarization through blockade of efferocytosis. Cell 
Death Dis. 2015;6(6):e1780-e1780. doi:10.1038/cddis.2015.144 
160.  Pikarsky E, Porat RM, Stein I, et al. NF-kB functions as a tumour promoter in 
inflammation-associated cancer. 2004;431:6. 
161.  Wells AD, Walsh MC, Bluestone JA, Turka LA. Signaling through CD28 and CTLA-4 
controls two distinct forms of T cell anergy. J Clin Invest. 2001;108(6):895-903. 
doi:10.1172/JCI13220 
162.  Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates 
induction of anergy in vivo. Immunity. 2001;14(2):145-155. doi:10.1016/s1074-
7613(01)00097-8 
163.  Wang J-C, Xu Y, Huang Z-M, Lu X-J. T cell exhaustion in cancer: Mechanisms and 
clinical implications. J Cell Biochem. 2018;119(6):4279-4286. doi:10.1002/jcb.26645 
164.  Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR Activation Mediates 
the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune 
 
60 
Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol Off Publ 
Int Assoc Study Lung Cancer. 2015;10(6):910-923. 
doi:10.1097/JTO.0000000000000500 
165.  Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response 
through CD47 and PD-L1. Science. 2016;352(6282):227-231. 
doi:10.1126/science.aac9935 
166.  Lucas J, Hsieh T-C, Halicka HD, Darzynkiewicz Z, Wu JM. Upregulation of PD-L1 
expression by resveratrol and piceatannol in breast and colorectal cancer cells 
occurs via HDAC3/p300-mediated NF-κB signaling. Int J Oncol. 2018;53(4):1469-
1480. doi:10.3892/ijo.2018.4512 
167.  Fogarty CE, Bergmann A. Killers creating new life: caspases drive apoptosis-induced 
proliferation in tissue repair and disease. Cell Death Differ. 2017;24(8):1390-1400. 
doi:10.1038/cdd.2017.47 
 
 
61 
CIRRICULUM VITAE 
 
62 
 
63 
 
 
 
 
 
 
